Thursday, 8 December 2011

Treatment of clinically isolated syndrome with interferon beta 1a reduces the risk of conversion to MS

Source MS Trust:
Results from the REFLEX study (REbif FLEXible dosing in early MS) show that interferon beta 1a delayed clincal relapse and subclinical disease activity in people with clinically isolated syndrome whether given once or three times a week. An earlier study (ETOMS) found that 22mg of interferon beta 1a once a week was effective in delaying the diagnosis of MS, this study compared the effects of two dosing regimes with placebo.  For more click here.